Health Industry Initiatives by Trump and Kennedy Face Uncertain Future

In the midst of his competitive reelection campaign in Michigan, Republican Representative Tom Barrett joined HHS Secretary Robert F. Kennedy Jr. at an expansive 400-acre apple orchard, farm, and winery. They highlighted efforts made during the Trump administration aimed at improving the American diet, such as the elimination of certain artificial dyes from processed foods.

Barrett stated, ‘We had a great discussion about healthy options for all Americans and taking back control of our healthcare,’ following a sampling of the farm’s apple cider.

However, many of the administration’s most prominent health initiatives depend on voluntary agreements. Goals like reducing drug prices and providing nutrition classes for medical professionals resonate with a broad audience, transcending political and economic divides.

Yet, these administration-industry agreements lack the enforcement mechanisms typical of more traditional federal regulations. The specifics of these deals are often ambiguous, and minimal oversight complicates the monitoring of progress. In certain instances, the administration has claimed victories that have yet to be fulfilled.

Republicans perceive this deal-making strategy as a successful approach, aligning with the party’s anti-regulatory philosophy. It allows the administration to swiftly establish agreements that President Donald Trump and his supporters can present as achievements. As the November midterm elections approach, some, including Barrett, aim to attract voters by touting the administration’s health policy initiatives.

This situation raises significant questions. Despite grand announcements made in public forums—often broadcast live with enthusiastic audiences—there’s frequently a lack of thorough documentation or follow-up, which raises doubts about the potential for these health initiatives to produce meaningful and lasting changes.

The clarity of these distinctions may become crucial as Republicans defend their health records in the imminent midterm elections.

‘These deals are often not transparent, preventing the public from assessing their significance,’ commented Larry Levitt, Executive Vice President for Health Policy at KFF, a health information nonprofit.

Focus on Artificial Dyes

The push to eliminate specific artificial dyes from food and medications has garnered considerable attention. In April 2025, Kennedy made a highly publicized announcement regarding agreements with food manufacturers, joined on stage by children and mothers holding signs reading ‘Make America Healthy Again.’

During this appearance, he, along with former FDA commissioner Marty Makary, MD, received applause as they declared that companies had committed to phasing out all petroleum-based synthetic dyes from the nation’s food supply and medications, targeting nine synthetic dyes in total.

Voter sentiment strongly supports the idea of eliminating these dyes. A nationally representative survey conducted in March by Consumer Reports revealed that 72% of adults expressed some degree of concern regarding synthetic dyes, with two-thirds advocating for a mandatory phase-out.

A year after the initial announcement, Kennedy declared a successful outcome during a session at the Conservative Political Action Conference (CPAC), saying, ‘We’ve gotten rid of the nine synthetic-based food dyes.’

However, this claim lacks accuracy. At the beginning of the HHS event, federal officials indicated that companies would voluntarily discontinue six specific synthetic dyes by the end of the year. (The administration has also involved efforts to revoke authorization for two other synthetic food dyes.)

More recently, the FDA quietly extended the deadline to the end of 2027, indicating that the majority of these dyes remain in circulation.

According to the FDA, as of December 2025, 27 companies had made voluntary commitments to eliminate six synthetic dyes from products like Doritos and Kellogg’s Froot Loops. However, more than a year and a half later, only seven food manufacturers—fewer than 30% of those that committed—had fulfilled their promised goals.

Major food producers like Coca-Cola and Unilever have reportedly made ‘no concrete commitments’ to remove synthetic dyes, according to Consumer Reports. Furthermore, no pharmaceutical companies have publicly declared intentions to eliminate dyes from medications.

‘It’s just all talk,’ asserted Leslie Dach, chair of Protect Our Care, a healthcare advocacy organization supporting the Affordable Care Act. ‘They create public relations spectacles and then move on, leaving little change behind. Many people remain unaware of this because they’re busy, leading them to perceive an abundance of initiatives that, in reality, yield little result.’

Indeed, the administration has relaxed labeling requirements, permitting companies to claim their products are free from artificial colors, as long as they do not use petroleum-based dyes. Previously, manufacturers could only make such claims if their products contained no added colors. However, some naturally derived food dyes could also contain contaminants, potentially posing health risks, including an association with diabetes.

‘The federal government has not initiated significant regulatory actions concerning food dyes since this administration commenced,’ remarked Melanie Benesh, Vice President for Government Affairs at the Environmental Working Group.

HHS asserted that the voluntary strategy has prompted substantial actions, including initiatives to eliminate synthetic dyes from products sold in schools for the 2026-2027 academic year.

According to an HHS spokesperson, ‘HHS and the FDA are proceeding with established timelines and firm industry commitments, with substantial modifications anticipated in food products served in schools during the upcoming school year and across complete product lines by late 2027.’

During the same CPAC event, Kennedy alluded to changes in educational assessments related to nutrition, suggesting a collaboration with MCAT test developers. However, this statement was inaccurately presented, as the test is overseen by the Association of American Medical Colleges.

Concerns About Insurance Agreements

Again on stage during a June 2025 event, Kennedy, alongside CMS Administrator Mehmet Oz, MD, announced what was touted as a transformative agreement involving major insurers agreeing to reduce the volume of healthcare services requiring prior authorization.

The administration claimed that 80% of insurers committed to alter preauthorization prerequisites for 80% of diseases and injuries by January 2026. They also promised to introduce ‘public dashboards’ to monitor progress.

However, several months post the January deadline, health plans have managed a mere 11% reduction in prior authorization requirements, and public dashboards have yet to appear. Some insurers have indicated that they will not enact all the promised reforms as envisioned.

The American Medical Association (AMA) conducted a survey in 2025 with 1,000 practicing physicians, asking if they believed the voluntary pledges would have a meaningful impact. Only one in three respondents expressed confidence in their effectiveness.

Insurers had previously made similar commitments in 2018 during the preceding Trump administration; nonetheless, over 80% of doctors reported an increase in prior authorization requests the subsequent year.

Impact of Deregulation

Many voters are drawn to the healthcare industry’s voluntary agreements, believing that government regulations inflate costs and impose undue burdens on businesses._

Some proponents, such as political consultant David Mansdoerfer, argue that Secretary Kennedy embodies an approach that favors communication over coercion, advocating for voluntary initiatives rather than government mandates.

However, the efficacy of such agreements can often be questionable. Historical examples, like former President Jimmy Carter’s 1977 legislative attempt to control hospital costs, reflect industry resistance to mandatory regulatory approaches, leading to a preference for voluntary solutions that ultimately failed to achieve desired outcomes.

One advantage of voluntary deals is their rapid implementation. Creating federal regulations can take several years, and some health analysts assert that the pace of agreements pursued by Kennedy and Trump may assist in diverting public focus from the administration’s inability to deliver a long-promised health plan.

Instead, Republicans can point to the extensive agreements established with industry, including the administration’s voluntary arrangement with pharmaceutical companies aimed at price reductions, referred to as the ‘most-favored-nation’ drug pricing policy.

Seventeen pharmaceutical companies, including Pfizer and AstraZeneca, have commenced agreements with the administration to drive down prices for Medicaid recipients and cash-paying consumers through TrumpRx, a limited government-run consumer platform. Despite numerous details remaining unspecified, it has been claimed that these price reductions pertain solely to new and existing drugs accessed through Medicaid, with TrumpRx prices not consistently lower than out-of-pocket expenses for most insured consumers.

Although policies that would lead to drug price reductions may concern investors due to potential profit declines, drug companies generally experienced positive market responses following the announcements of the agreements.

This may be attributed to the narrow scope of the deals, which largely remain theoretical and do not encompass existing medications prescribed to over 200 million Americans carrying commercial or private health insurance.

Nonetheless, the Trump administration persists in claiming success regarding these initiatives. ‘The most-favored-nation agreements on drug prices are producing the largest cuts in history,’ Trump declared during a June address, asserting, ‘That alone should secure our victory in the midterms.’

Disclaimer: The information presented in this article is for educational purposes only and should not be considered medical advice. Always seek the advice of your healthcare provider with any questions you may have regarding a medical condition or treatment.

Fuente: https://www.medpagetoday.com/publichealthpolicy/washington-watch/122859